(Q45421316)

English

Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

based on heuristic

inferred from title

3

object named as

Leo Heyndrickx

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Fatim Cham

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Peng Fei Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Peter Bouma

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Ping Zhong

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Herman Katinger

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

James Robinson

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Guido van der Groen

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Gerald V Quinnan

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

27 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

number of pages

16

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

347

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

36-51

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Escherichia coli expression, purification, and biological activity of a truncated soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

CLUSTAL: a package for performing multiple sequence alignment on a microcomputer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Progress towards the development of a HIV-1 gp41-directed vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Urgently needed: a filter for the HIV-1 vaccine pipeline

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Immunology. Close to the edge: neutralizing the HIV-1 envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Comparing antigenicity and immunogenicity of engineered gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Solid-state NMR yields structural constraints on the V3 loop from HIV-1 Gp120 bound to the 447-52D antibody Fv fragment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Preparation and characterization of human HIV type 1 neutralizing reference sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.11.019

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.11.019

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45421316&oldid=2076909150"